Generic Name and Formulations:
Butalbital 50mg, acetaminophen 325mg, caffeine 40mg; tabs; caps.
Various generic manufacturers
- Dexcom G6 Integrated Continuous Glucose Monitoring System Gets FDA Approval
- New Continuous Glucose Monitoring System Now Available for Medicare Patients
- Acetaminophen Interference With Blood Glucose Readings: What Clinicians Need to Know
Indications for Butalbital/Acetaminophen/Caffeine:
Tension (or muscle contraction) headache.
1–2 tabs or caps every 4hrs as needed; max 6 daily.
Drug abusers. Severe hepatic or renal impairment (monitor). Acute abdominal conditions. Discontinue if serious skin rash or hypersensitivity reactions occur. Elderly. Debilitated. Pregnancy (Cat.C). Nursing mothers: not recommended.
May potentiate effects of alcohol, general anesthetics, tranquilizers, sedative-hypnotics, or other CNS depressants or narcotic analgesics; avoid. MAOIs may enhance CNS effects of butalbital. May cause false (+) urine test for 5-hydroxyindoleacetic acid.
Barbiturate + analgesic.
Drowsiness, lightheadedness, dizziness, sedation, shortness of breath, nausea, vomiting, abdominal pain, intoxicated feeling; hepatotoxicity (APAP doses >4g/day); rare: serious skin reactions, hypersensitivity.
Formerly known under the brand name Esgic.
Endocrinology Advisor Articles
- Soluble Klotho Levels Predictive of Kidney Failure in Type 2 Diabetes
- HbA1c Levels Predictive of Liraglutide Treatment Response in T2D
- Comorbid and Pharmacologic Factors Increase Risk for Gastrointestinal Disorders in Diabetes
- ADA Updates Guidelines for Cardiovascular Risk Management in Diabetes
- Clinicians May Be Overtreating Older Patients With Diabetes
- USPSTF Issues Recommendation for Vitamin D, Calcium Supplementation for Fracture Prevention
- Obesity Risk in Infants Born to Women With Diabetes
- Insulin-Treated Diabetes Reduces Dysglycemia-Related Mortality in Sepsis
- Increased Risk for Mortality in People With Diabetes, CHD Taking Beta-Blockers
- Oxyntomodulin Augments Glucose Homeostasis